TYK Medicines, Inc (HKG:2410)
Hong Kong
· Delayed Price · Currency is HKD
11.10
-0.09 (-0.80%)
Mar 10, 2026, 4:08 PM HKT
TYK Medicines Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
| TTM
| FY 2024 | FY 2023 | FY 2022 |
| Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
| Revenue | 0.11 | 0.11 | - | 44.24 |
| Cost of Revenue | 0.09 | 0.09 | - | 24.2 |
| Gross Profit | 0.01 | 0.01 | - | 20.04 |
| Selling, General & Admin | 107.01 | 108.33 | 59.31 | 33.54 |
| Research & Development | 186.45 | 235.45 | 249.25 | 229.81 |
| Operating Expenses | 293.45 | 343.78 | 308.56 | 263.35 |
| Operating Income | -293.44 | -343.76 | -308.56 | -243.31 |
| Interest Expense | -14.49 | -12.57 | -8.73 | -3.26 |
| Interest & Investment Income | 7.97 | 3.28 | 3.73 | 7.37 |
| Currency Exchange Gain (Loss) | -1.33 | 0.29 | 0.1 | - |
| Other Non Operating Income (Expenses) | 19.05 | -35.21 | -68.98 | -72.87 |
| EBT Excluding Unusual Items | -282.24 | -387.97 | -382.44 | -312.06 |
| Gain (Loss) on Sale of Investments | -0.26 | -0 | -0.73 | 0.34 |
| Gain (Loss) on Sale of Assets | 0.04 | 0.04 | -0.01 | -0.04 |
| Other Unusual Items | - | 0 | 0.01 | -0.05 |
| Pretax Income | -282.46 | -387.93 | -383.17 | -311.8 |
| Earnings From Continuing Operations | -282.46 | -387.93 | -383.17 | -311.8 |
| Minority Interest in Earnings | 2.38 | 0.97 | 0.74 | 0.81 |
| Net Income | -280.08 | -386.96 | -382.43 | -310.99 |
| Net Income to Common | -280.08 | -386.96 | -382.43 | -310.99 |
| Shares Outstanding (Basic) | 363 | 338 | 289 | 278 |
| Shares Outstanding (Diluted) | 363 | 338 | 289 | 278 |
| Shares Change (YoY) | 18.99% | 16.91% | 3.94% | - |
| EPS (Basic) | -0.77 | -1.15 | -1.32 | -1.12 |
| EPS (Diluted) | -0.77 | -1.15 | -1.32 | -1.12 |
| Free Cash Flow | -321.48 | -381.87 | -277.32 | -279.02 |
| Free Cash Flow Per Share | -0.89 | -1.13 | -0.96 | -1.00 |
| Gross Margin | 13.08% | 13.08% | - | 45.30% |
| Operating Margin | -274242.06% | -321274.77% | - | -549.94% |
| Profit Margin | -261756.08% | -361640.19% | - | -702.94% |
| Free Cash Flow Margin | -300449.53% | -356891.59% | - | -630.67% |
| EBITDA | -279.8 | -328.83 | -295.1 | -232.31 |
| D&A For EBITDA | 13.64 | 14.93 | 13.46 | 11 |
| EBIT | -293.44 | -343.76 | -308.56 | -243.31 |
Source: S&P Capital IQ. Standard template.
Financial Sources.